101 related articles for article (PubMed ID: 28704165)
1. Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.
Casnici C; Crotta K; Volpe G; Panuzzo C; Lattuada D; Mesiano G; Saglio G; Marelli O
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):149-156. PubMed ID: 28704165
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
[TBL] [Abstract][Full Text] [Related]
3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
4. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
[TBL] [Abstract][Full Text] [Related]
5. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
[TBL] [Abstract][Full Text] [Related]
6. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
Leukemia; 1992 Nov; 6(11):1107-12. PubMed ID: 1434792
[TBL] [Abstract][Full Text] [Related]
7. New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia.
Panuzzo C; Volpe G; Cibrario Rocchietti E; Casnici C; Crotta K; Crivellaro S; Carrà G; Lorenzatti R; Peracino B; Torti D; Morotti A; Camacho-Leal MP; Defilippi P; Marelli O; Saglio G
Oncoscience; 2015; 2(10):880-91. PubMed ID: 26682280
[TBL] [Abstract][Full Text] [Related]
8. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
9. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
10. [Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Shi HL; Qiu JY; Lu DP; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):409-12. PubMed ID: 15355693
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
[TBL] [Abstract][Full Text] [Related]
14. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
15. Exon-skipping in BCR/ABL is induced by ABL exon 2.
Lichty BD; Kamel-Reid S
Biochem J; 2000 May; 348 Pt 1(Pt 1):63-9. PubMed ID: 10794714
[TBL] [Abstract][Full Text] [Related]
16. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
17. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
[TBL] [Abstract][Full Text] [Related]
18. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Kelani R; Monem F
Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
